stockportfolio.pro
Bruker Corporation (BRKR)
Healthcare · Medical Devices · NasdaqGS
Bruker Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.61B | $1.77B | $1.90B | $2.07B | $1.99B | $2.42B | $2.53B | $2.96B | $3.37B | $3.44B |
| Gross profit | $745.30M | $816.00M | $900.00M | $995.30M | $939.80M | $1.21B | $1.31B | $1.51B | $1.65B | $1.58B |
| Net income | $153.60M | $78.60M | $179.70M | $197.20M | $157.80M | $277.10M | $296.60M | $427.20M | $113.10M | $-22.50M |
| Net margin | 9.5% | 4.5% | 9.5% | 9.5% | 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.7% |
Source: Bruker Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Bruker Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BRKR in your portfolio →
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Bruker Corporation — frequently asked questions
What is Bruker Corporation's revenue?
Bruker Corporation (BRKR) reported revenue of $3.44B for fiscal year 2025, up 2.1% from the prior year, according to its SEC filings.
Is Bruker Corporation profitable?
No — BRKR reported a net loss of $-22.50M in fiscal 2025.
What is BRKR's P/E ratio?
Bruker Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Bruker Corporation growing?
BRKR's revenue grew at roughly 11.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Bruker Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.